-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In 2021, China's pharmaceutical companies will show a rapid growth trend in terms of the overall development trend
.
Data show that from January to September 2021, the operating income of pharmaceutical enterprises above designated size in China increased by 24.
4% year-on-year to 2,129.
1 billion yuan; total profits increased by 80.
6% year-on-year to 452.
53 billion yuan
.
By 2022, the state will also continue to help the pharmaceutical industry grow steadily
.
In this article, the author has collected some pharmaceutical stocks that have increased significantly since 2022
.
Asia Pacific Pharmaceuticals: an increase of 114.
06% since 2022 Recently, the two cities have been hyping the concept of "Helicobacter pylori"
.
Asia Pacific Pharmaceuticals has risen 114.
06% since 2022
.
Asia Pacific Pharmaceutical stated on the interactive platform that the company's digestive system drugs mainly include pantoprazole sodium for injection, omeprazole sodium for injection, omeprazole enteric-coated capsules, lansoprazole enteric-coated capsules, etc.
, which belong to proton pump inhibitor
.
The current treatment regimen for Helicobacter pylori mainly includes proton pump inhibitors and gastric mucosal protective agents, combined with one or two antibiotics, and triple or quadruple therapy can be used
.
After the stock price rose sharply, Asia Pacific Pharmaceuticals announced that the shareholder Bank of Ningbo would liquidate Asia Pacific Pharmaceuticals
.
It is reported that Asia Pacific Pharmaceuticals announced on the evening of January 11 that the 7.
27% shareholder Bank of Ningbo plans to empty its 39 million shares and transfer them all to Fubon Group, a major shareholder.
The transaction price is 5.
21 yuan per share, and the total transfer price The amount is 203 million yuan
.
However, analysts pointed out that from a fundamental point of view, the Asia-Pacific pharmaceutical industry is hardly optimistic
.
Data shows that in 2019, Asia Pacific Pharmaceuticals lost more than 2 billion yuan; in 2020, its net profit increased by 101.
42% year-on-year to 27.
27 million yuan; in the first three quarters of 2021, revenue fell by 39.
5% year-on-year, with a loss of 95.
11 million yuan
.
Haichen Pharmaceutical: 103.
15% increase since 2022 Haichen Pharmaceutical has also embraced the concept of "Helicobacter pylori", with an increase of 103.
15% since 2022
.
However, analysts pointed out that the main drugs of Haichen Pharmaceutical are only related to the treatment of gastric diseases, and cannot belong to the concept stocks of "Helicobacter pylori" in the full sense
.
According to the data, the core categories of Haichen Pharmaceutical are diuretics and antibiotics.
The main diuretic products are torasemide, and the antibiotic products include: cefotiam hydrochloride, cefoxidone, and tigecycline
.
Regarding the market hype, Haichen Pharmaceutical issued an announcement saying that the company's recent operations were normal, and the internal and external operating environment had not undergone major changes
.
It is reported that before the stock price fluctuated, Haichen Pharmaceutical issued an announcement stating that the company received the "Approval Letter for Supplementary Drug Application" for the company's product esomeprazole sodium for injection, which was approved and issued by the State Food and Drug Administration.
, the product has passed the consistency evaluation of generic drug quality and efficacy
.
The company's esomeprazole sodium for injection is a new generation of proton pump inhibitor, which is mainly suitable for peptic ulcer, acute gastric mucosal damage complicated by stress state,
etc.
Kaikai Industry: 100.
12% increase since 2022 Kaikai Industry has increased 100.
12% since 2022
.
It is reported that the continuous daily limit of Kaikai Industrial's share price is closely related to recent market rumors that its wholly-owned subsidiary Shanghai Leiyunshang Pharmaceutical West Co.
, Ltd.
has the national secret formula of Liushen Pills
.
However, Kaikai Industry stated that Liushen Pill is not a product produced by the company's pharmaceutical sector, but all the specialty stores and online platforms of the company's Lei Yunshang Pharmaceutical have Liushen Pill for sale, and it does not have the mentioned "Liu Shen Pill".
Pharmaceutical formula
.
According to the data, Kaikai Industry is mainly engaged in the circulation of traditional Chinese medicine, traditional Chinese medicine services (traditional Chinese medicine consultation services) and clothing production and sales
.
Among them, the pharmaceutical industry is mainly the wholesale and retail of Chinese and Western patent medicines, as well as the sales of traditional Chinese medicine services under the brand of "Lei Yunshang" and the sales of self-owned brand "Shanglei" brand tonics
.
Data shows that Kaikai Industrial has shown a state of increasing revenue but not increasing profits in the past ten years
.
For example, from 2018 to 2020, its revenue was 878 million yuan, 870 million yuan, and 762 million yuan respectively, but its net profit was only 35.
1421 million yuan, 21.
6752 million yuan, and 12.
9059 million yuan respectively
.
In the first three quarters of 2021, the operating income of the pharmaceutical wholesale and pharmaceutical retail sectors, which account for a larger proportion of the pharmaceutical sector, fell by 29.
22% and 11.
33% year-on-year, respectively
.
Anxu Bio: Up 96.
93% since 2022 As a new stock on the Science and Technology Innovation Board, Anxu Bio has risen from the ground up, with an increase of 96.
93% since 2022
.
According to the data, Anxu Bio was established in 2008, focusing on the research and development of POCT (point-of-care) reagents and instruments.
Original detection and other POCT reagents in eight fields
.
As a company in the field of medical devices, Anxu Bio has achieved relatively stable growth in performance due to its integrated advantages in the layout of upstream raw materials
.
It is reported that Anxu Bio’s revenue mainly comes from POCT reagents independently developed and produced.
.
The data shows that the company's revenue in the first three quarters of 2018, 2019, 2020, and 2021 was 164 million yuan, 210 million yuan, 1.
199 billion yuan, and 682 million yuan, respectively, and the corresponding net profits for the same period were 33.
4093 million yuan and 54.
4476 million yuan respectively.
, 649 million yuan, 284 million yuan
.
Rejing Bio: 79.
77% increase since 2022 According to the 2021 performance forecast released by Rejing Bio, its net profit attributable to the parent in 2021 is expected to increase by as much as 1684.
65% to 1996.
97% year-on-year, ranging from 2 billion to 2.
35 billion yuan
.
The explosive performance has caused agitation in the "hot money" in the capital market
.
It has increased by 79.
77% since 2022.
On January 7, the share price of Rejing Biotech rose strongly by 20%, closing at the daily limit of 156.
56 yuan
.
According to the data, Rejing Bio is a biological enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments.
It has built a full-scene immunodiagnosis platform that can meet the needs of different end users.
It is one of the few products in the industry that covers full-scene applications.
one of the suppliers
.
It is reported that, at present, Rejing Bio has entered the in vitro diagnostic market segment, including immunodiagnosis, POCT, molecular diagnosis and other fields, and has strategically deployed the research and development of therapeutic antibody drugs
.
The company has been at a high level in the field of early diagnosis of hepatitis and liver cancer, and has achieved obvious competitive advantages in the fields of cardiovascular and cerebrovascular diagnosis, inflammation and infection diagnosis
.
In addition to the above companies, Aotai Bio has increased by 78.
68% since 2022; Botuo Bio: increased by 75.
25% since 2022; Sailong Pharmaceutical: increased by 73.
21% since 2022; Jiu’an Medical: increased by 67.
12% since 2022; Red Pharma: 61.
90% increase since 2022; Hanyu Pharmaceutical: 60.
98% increase since 2022
.
.
Data show that from January to September 2021, the operating income of pharmaceutical enterprises above designated size in China increased by 24.
4% year-on-year to 2,129.
1 billion yuan; total profits increased by 80.
6% year-on-year to 452.
53 billion yuan
.
By 2022, the state will also continue to help the pharmaceutical industry grow steadily
.
In this article, the author has collected some pharmaceutical stocks that have increased significantly since 2022
.
Asia Pacific Pharmaceuticals: an increase of 114.
06% since 2022 Recently, the two cities have been hyping the concept of "Helicobacter pylori"
.
Asia Pacific Pharmaceuticals has risen 114.
06% since 2022
.
Asia Pacific Pharmaceutical stated on the interactive platform that the company's digestive system drugs mainly include pantoprazole sodium for injection, omeprazole sodium for injection, omeprazole enteric-coated capsules, lansoprazole enteric-coated capsules, etc.
, which belong to proton pump inhibitor
.
The current treatment regimen for Helicobacter pylori mainly includes proton pump inhibitors and gastric mucosal protective agents, combined with one or two antibiotics, and triple or quadruple therapy can be used
.
After the stock price rose sharply, Asia Pacific Pharmaceuticals announced that the shareholder Bank of Ningbo would liquidate Asia Pacific Pharmaceuticals
.
It is reported that Asia Pacific Pharmaceuticals announced on the evening of January 11 that the 7.
27% shareholder Bank of Ningbo plans to empty its 39 million shares and transfer them all to Fubon Group, a major shareholder.
The transaction price is 5.
21 yuan per share, and the total transfer price The amount is 203 million yuan
.
However, analysts pointed out that from a fundamental point of view, the Asia-Pacific pharmaceutical industry is hardly optimistic
.
Data shows that in 2019, Asia Pacific Pharmaceuticals lost more than 2 billion yuan; in 2020, its net profit increased by 101.
42% year-on-year to 27.
27 million yuan; in the first three quarters of 2021, revenue fell by 39.
5% year-on-year, with a loss of 95.
11 million yuan
.
Haichen Pharmaceutical: 103.
15% increase since 2022 Haichen Pharmaceutical has also embraced the concept of "Helicobacter pylori", with an increase of 103.
15% since 2022
.
However, analysts pointed out that the main drugs of Haichen Pharmaceutical are only related to the treatment of gastric diseases, and cannot belong to the concept stocks of "Helicobacter pylori" in the full sense
.
According to the data, the core categories of Haichen Pharmaceutical are diuretics and antibiotics.
The main diuretic products are torasemide, and the antibiotic products include: cefotiam hydrochloride, cefoxidone, and tigecycline
.
Regarding the market hype, Haichen Pharmaceutical issued an announcement saying that the company's recent operations were normal, and the internal and external operating environment had not undergone major changes
.
It is reported that before the stock price fluctuated, Haichen Pharmaceutical issued an announcement stating that the company received the "Approval Letter for Supplementary Drug Application" for the company's product esomeprazole sodium for injection, which was approved and issued by the State Food and Drug Administration.
, the product has passed the consistency evaluation of generic drug quality and efficacy
.
The company's esomeprazole sodium for injection is a new generation of proton pump inhibitor, which is mainly suitable for peptic ulcer, acute gastric mucosal damage complicated by stress state,
etc.
Kaikai Industry: 100.
12% increase since 2022 Kaikai Industry has increased 100.
12% since 2022
.
It is reported that the continuous daily limit of Kaikai Industrial's share price is closely related to recent market rumors that its wholly-owned subsidiary Shanghai Leiyunshang Pharmaceutical West Co.
, Ltd.
has the national secret formula of Liushen Pills
.
However, Kaikai Industry stated that Liushen Pill is not a product produced by the company's pharmaceutical sector, but all the specialty stores and online platforms of the company's Lei Yunshang Pharmaceutical have Liushen Pill for sale, and it does not have the mentioned "Liu Shen Pill".
Pharmaceutical formula
.
According to the data, Kaikai Industry is mainly engaged in the circulation of traditional Chinese medicine, traditional Chinese medicine services (traditional Chinese medicine consultation services) and clothing production and sales
.
Among them, the pharmaceutical industry is mainly the wholesale and retail of Chinese and Western patent medicines, as well as the sales of traditional Chinese medicine services under the brand of "Lei Yunshang" and the sales of self-owned brand "Shanglei" brand tonics
.
Data shows that Kaikai Industrial has shown a state of increasing revenue but not increasing profits in the past ten years
.
For example, from 2018 to 2020, its revenue was 878 million yuan, 870 million yuan, and 762 million yuan respectively, but its net profit was only 35.
1421 million yuan, 21.
6752 million yuan, and 12.
9059 million yuan respectively
.
In the first three quarters of 2021, the operating income of the pharmaceutical wholesale and pharmaceutical retail sectors, which account for a larger proportion of the pharmaceutical sector, fell by 29.
22% and 11.
33% year-on-year, respectively
.
Anxu Bio: Up 96.
93% since 2022 As a new stock on the Science and Technology Innovation Board, Anxu Bio has risen from the ground up, with an increase of 96.
93% since 2022
.
According to the data, Anxu Bio was established in 2008, focusing on the research and development of POCT (point-of-care) reagents and instruments.
Original detection and other POCT reagents in eight fields
.
As a company in the field of medical devices, Anxu Bio has achieved relatively stable growth in performance due to its integrated advantages in the layout of upstream raw materials
.
It is reported that Anxu Bio’s revenue mainly comes from POCT reagents independently developed and produced.
.
The data shows that the company's revenue in the first three quarters of 2018, 2019, 2020, and 2021 was 164 million yuan, 210 million yuan, 1.
199 billion yuan, and 682 million yuan, respectively, and the corresponding net profits for the same period were 33.
4093 million yuan and 54.
4476 million yuan respectively.
, 649 million yuan, 284 million yuan
.
Rejing Bio: 79.
77% increase since 2022 According to the 2021 performance forecast released by Rejing Bio, its net profit attributable to the parent in 2021 is expected to increase by as much as 1684.
65% to 1996.
97% year-on-year, ranging from 2 billion to 2.
35 billion yuan
.
The explosive performance has caused agitation in the "hot money" in the capital market
.
It has increased by 79.
77% since 2022.
On January 7, the share price of Rejing Biotech rose strongly by 20%, closing at the daily limit of 156.
56 yuan
.
According to the data, Rejing Bio is a biological enterprise engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments.
It has built a full-scene immunodiagnosis platform that can meet the needs of different end users.
It is one of the few products in the industry that covers full-scene applications.
one of the suppliers
.
It is reported that, at present, Rejing Bio has entered the in vitro diagnostic market segment, including immunodiagnosis, POCT, molecular diagnosis and other fields, and has strategically deployed the research and development of therapeutic antibody drugs
.
The company has been at a high level in the field of early diagnosis of hepatitis and liver cancer, and has achieved obvious competitive advantages in the fields of cardiovascular and cerebrovascular diagnosis, inflammation and infection diagnosis
.
In addition to the above companies, Aotai Bio has increased by 78.
68% since 2022; Botuo Bio: increased by 75.
25% since 2022; Sailong Pharmaceutical: increased by 73.
21% since 2022; Jiu’an Medical: increased by 67.
12% since 2022; Red Pharma: 61.
90% increase since 2022; Hanyu Pharmaceutical: 60.
98% increase since 2022
.
